Prognostic Impact of the Increase in Cardiac Troponin Levels during Tafamidis Therapy in Patients with Transthyretin Cardiac Amyloidosis

Background: Recent clinical trials have demonstrated that tafamidis (Pfizer Inc., New York, NY, USA) reduced all-cause mortality and the number of cardiovascular hospitalizations compared with placebo in patients with transthyretin cardiac amyloidosis. However, the optimal surrogate markers during t...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Makiko, Imamura, Teruhiko, Ushijima, Ryuichi, Kinugawa, Koichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380493/
https://www.ncbi.nlm.nih.gov/pubmed/37510746
http://dx.doi.org/10.3390/jcm12144631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380493/
https://www.ncbi.nlm.nih.gov/pubmed/37510746
http://dx.doi.org/10.3390/jcm12144631

Ejemplares similares